“This added capacity, a key component of our global growth and expansion strategy, supports our customers’ needs for faster, more convenient clinical trial testing and delivery across EMEA,” said ...

Firms claim microfluidics-based system will provide early indicator of drug response. LabCorp negotiated rights to market cancer diagnostics firm On-Q-ity’s circulating tumor cell (CTC) platform to ...

(Reuters) - Laboratory Corp of America Holdings missed estimates for quarterly profit on Tuesday, as its drug development unit struggled against curbs on animal imports, while a sharp fall in sales of ...

The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.